Safety and cardiovascular effects of multiple‐dose administration of aripiprazole and olanzapine in a randomised clinical trial - Koller - 2021 - Human Psychopharmacology: Clinical and Experimental - Wiley Online Library

PDF) Safety and cardiovascular effects of multiple-dose administration of aripiprazole and olanzapine in a randomised clinical trial

Frontiers Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone

Frontiers Characteristics and Spectrum of Cardiotoxicity Induced by Various Antipsychotics: A Real-World Study From 2015 to 2020 Based on FAERS

Recent advances in dopamine D2 receptor ligands in the treatment of neuropsychiatric disorders - Juza - 2023 - Medicinal Research Reviews - Wiley Online Library

PDF) Evidence-Based Recommendations for Monitoring Safety of Second Generation Antipsychotics in Children and Youth

Antipsychotic - Wikipedia

A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder

The effects of aripiprazole and olanzapine on pupillary light reflex and its relationship with pharmacogenetics in a randomized multiple‐dose trial - Koller - 2020 - British Journal of Clinical Pharmacology - Wiley Online Library

A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder

The impact of adjunctive aripiprazole on QT interval: A 12‐week open label study in patients on olanzapine, clozapine or risperidone - Pilunthanakul - 2023 - Human Psychopharmacology: Clinical and Experimental - Wiley Online Library

Role of Aripiprazole in the Treatment of Cardiovascular Disease

Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews

A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder

Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in